Incidence and impact on prognosis of peri-procedural myocardial infarction in 2760 elective patients with stable angina pectoris in a historical prospective follow-up study

BACKGROUND: The clinical significance of myocardial infarction related to treatment with percutaneous coronary intervention (PCI) has been subject of great discussion. This subject has been studied for many years using different definitions of peri-procedural myocardial infarction and different biomarkers, the results have varied greatly depending on methods and time of the study. This study was to determine the incidence and prognostic significance of elevated cardiac biomarkers after elective PCI in patients with stable angina pectoris using the current cut-off set by the Third Universal Definition of Myocardial Infarction and current biomarkers. METHODS: We performed a historical prospective follow-up study of all patients with stable angina pectoris who underwent elective PCI at Aalborg University Hospital, Denmark from January 1(st) 2000 to December 31(st) 2012. We stratified patients according to peak post-PCI troponin T (cTnT) and Creatine Kinase MB mass (CK-MBmass). RESULTS: Follow-up for time to all-cause mortality was mean 5.8 years and total 15,891 years and mean 3.7 years and total 10,160 years for the combined endpoint of all-cause mortality and new onset heart failure. During the follow up period 399 of 2760 patients died (14.5 %) and 1095 (39.7 %) suffered the combined endpoint. Post-PCI concentration of cTnT and CK-MBmass was elevated above the defined cut-off in 419 patients (15.2 %) and 113 patients (4.1 %) respectively. There was no statistically significant difference between the groups in stratified analysis of the hazard rates by time regarding all-cause mortality for cTnT nor CK-MBmass. Regarding the combined endpoint the results were ambiguous. The results were unchanged in multivariable analyses that included age and gender. CONCLUSION: The incidence of elevated biomarkers after elective PCI in patients with stable angina pectoris using the defined cut-off (>5 x URL) was 15.2 % using cTnT and 4.1 % using CK-MBmass. The independent prognostic value for both cardiac biomarkers of any cut-off showed no statistical significance for all-cause mortality, whereas the combined endpoint (all-cause mortality or new-onset heart failure) were ambiguous in both short- and long-term follow-up

Dose reconstruction including dynamic six-degree of freedom motion during prostate radiotherapy

© Published under licence by IOP Publishing Ltd. An in-house developed program for real-time reconstruction of motion-induced dose errors, DoseTracker, was extended to handle rotational target motion in addition to the previously implemented translational motion, and applied offline for prostate VMAT treatments. For translational motion, the motion-induced errors of DoseTracker were in good agreement with ground truth dose reconstructions performed in a commercial treatment planning system. For rotational motion, no ground truth was available, but DoseTracker showed that the VMAT dose is highly robust against static interfractional rotations but quite sensitive to dynamic intrafraction rotations due to interplay effects between target motion and machine motion

Type 2 myocardial infarction: the chimaera of cardiology?

The term type 2 myocardial infarction first appeared as part of the universal definition of myocardial infarction. It was introduced to cover a group of patients who had elevation of cardiac troponin but did not meet the traditional criteria for acute myocardial infarction although they were considered to have an underlying ischaemic aetiology for the myocardial damage observed. Since first inception, the term type 2 myocardial infarction has always been vague. Although attempts have been made to produce a systematic definition of what constitutes a type 2 myocardial infarction, it has been more often characterised by what it is not rather than what it is. Clinical studies that have used type 2 myocardial infarction as a diagnostic criterion have produced disparate incidence figures. The range of associated clinical conditions differs from study to study. Additionally, there are no agreed or evidence-based treatment strategies for type 2 myocardial infarction. The authors believe that the term type 2 myocardial infarction is confusing and not evidence-based. They consider that there is good reason to stop using this term and consider instead the concept of secondary myocardial injury that relates to the underlying pathophysiology of the primary clinical condition

Online 4D ultrasound guidance for real-time motion compensation by MLC tracking

PURPOSE: With the trend in radiotherapy moving toward dose escalation and hypofractionation, the need for highly accurate targeting increases. While MLC tracking is already being successfully used for motion compensation of moving targets in the prostate, current real-time target localization methods rely on repeated x-ray imaging and implanted fiducial markers or electromagnetic transponders rather than direct target visualization. In contrast, ultrasound imaging can yield volumetric data in real-time (3D + time = 4D) without ionizing radiation. The authors report the first results of combining these promising techniques-online 4D ultrasound guidance and MLC tracking-in a phantom. METHODS: A software framework for real-time target localization was installed directly on a 4D ultrasound station and used to detect a 2 mm spherical lead marker inside a water tank. The lead marker was rigidly attached to a motion stage programmed to reproduce nine characteristic tumor trajectories chosen from large databases (five prostate, four lung). The 3D marker position detected by ultrasound was transferred to a computer program for MLC tracking at a rate of 21.3 Hz and used for real-time MLC aperture adaption on a conventional linear accelerator. The tracking system latency was measured using sinusoidal trajectories and compensated for by applying a kernel density prediction algorithm for the lung traces. To measure geometric accuracy, static anterior and lateral conformal fields as well as a 358° arc with a 10 cm circular aperture were delivered for each trajectory. The two-dimensional (2D) geometric tracking error was measured as the difference between marker position and MLC aperture center in continuously acquired portal images. For dosimetric evaluation, VMAT treatment plans with high and low modulation were delivered to a biplanar diode array dosimeter using the same trajectories. Dose measurements with and without MLC tracking were compared to a static reference dose using 3%/3 mm and 2%/2 mm γ-tests. RESULTS: The overall tracking system latency was 172 ms. The mean 2D root-mean-square tracking error was 1.03 mm (0.80 mm prostate, 1.31 mm lung). MLC tracking improved the dose delivery in all cases with an overall reduction in the γ-failure rate of 91.2% (3%/3 mm) and 89.9% (2%/2 mm) compared to no motion compensation. Low modulation VMAT plans had no (3%/3 mm) or minimal (2%/2 mm) residual γ-failures while tracking reduced the γ-failure rate from 17.4% to 2.8% (3%/3 mm) and from 33.9% to 6.5% (2%/2 mm) for plans with high modulation. CONCLUSIONS: Real-time 4D ultrasound tracking was successfully integrated with online MLC tracking for the first time. The developed framework showed an accuracy and latency comparable with other MLC tracking methods while holding the potential to measure and adapt to target motion, including rotation and deformation, noninvasively

Potential improvements of lung and prostate MLC tracking investigated by treatment simulations.

PURPOSE/OBJECTIVES: Intrafraction tumor motion during external radiotherapy is a challenge for the treatment accuracy. A novel technique to mitigate the impact of tumor motion is real-time adaptation of the multileaf collimator (MLC) aperture to the motion, also known as MLC tracking. Although MLC tracking improves the dosimetric accuracy, there are still residual errors. Here, we investigate and rank the performance of five prediction algorithms and seven improvements of an MLC tracking system by extensive tracking treatment simulations. MATERIALS AND METHODS: An in-house-developed MLC tracking simulator that has been experimentally validated against an electromagnetic-guided MLC tracking system was used to test the prediction algorithms and tracking system improvements. The simulator requires a Dicom treatment plan and a motion trajectory as input and outputs all motion of the accelerator during MLC tracking treatment delivery. For lung tumors, MLC tracking treatments were simulated with a low and a high modulation VMAT plan using 99 patient-measured lung tumor trajectories. For prostate, tracking was also simulated with a low and a high modulation VMAT plan, but with 695 prostate trajectories. For each simulated treatment, the tracking error was quantified as the mean MLC exposure error, which is the sum of the overexposed area (irradiated area that should have been shielded according to the treatment plan) and the underexposed area (shielded area that should have been irradiated). First, MLC tracking was simulated with the current MLC tracking system without prediction, with perfect prediction (Perfect), and with the following five prediction algorithms: linear Kalman filter (Kalman), kernel density estimation (KDE), linear adaptive filtering (LAF), wavelet-based multiscale autoregression (wLMS), and time variant seasonal autoregression (TVSAR). Next, MLC tracking was simulated using the best prediction algorithm and seven different tracking system improvements: no localization signal latency (a), doubled maximum MLC leaf speed (b), halved MLC leaf width (c), use of Y backup jaws to track motion perpendicular to the MLC leaves (d), dynamic collimator rotation for alignment of the MLC leaves with the dominant target motion direction (e), improvements 4 and 5 combined (f), and all improvements combined (g). RESULTS: All results are presented as the mean residual MLC exposure error compared to no tracking. In the prediction study, the residual MLC exposure error was 47.0% (no prediction), 45.1% (Kalman), 43.8% (KDE), 43.7% (LAF), 42.1% (wLMS), 40.1% (TVSAR), and 36.5% (Perfect) for lung MLC tracking. For prostate MLC tracking, it was 66.0% (no prediction), 66.9% (Kalman), and 63.4% (Perfect). For lung with TVSAR prediction, the residual MLC exposure error for the seven tracking system improvements was 37.2%(1), 38.3%(2), 37.4%(3), 34.2%(4), 30.6%(5), 27.7%(6), and 20.7%(7). For prostate with no prediction, the residual MLC exposure error was 61.7%(1), 61.4%(2), 55.4%(3), 57.2%(4), 47.5%(5), 43.7%(6), and 38.7%(7). CONCLUSION: For prostate, MLC tracking was slightly better without prediction than with linear Kalman filter prediction. For lung, the TVSAR prediction algorithm performed best. Dynamic alignment of the collimator with the dominant motion axis was the most efficient MLC tracking improvement except for lung tracking with the low modulation VMAT plan, where jaw tracking was slightly better

Distance to invasive heart centre, performance of acute coronary angiography, and angioplasty and associated outcome in out-of-hospital cardiac arrest:a nationwide study

Aims To evaluate whether the distance from the site of event to an invasive heart centre, acute coronary angiography (CAG)/percutaneous coronary intervention (PCI) and hospital-level of care (invasive heart centre vs. local hospital) is associated with survival in out-of-hospital cardiac arrest (OHCA) patients. Methods and results Nationwide historical follow-up study of 41 186 unselected OHCA patients, in whom resuscitation was attempted between 2001 and 2013, identified through the Danish Cardiac Arrest Registry. We observed an increase in the proportion of patients receiving bystander CPR (18% in 2001, 60% in 2013, P &amp;lt; 0.001), achieving return of spontaneous circulation (ROSC) (10% in 2001, 29% in 2013, P &amp;lt; 0.001) and being admitted directly to an invasive centre (26% in 2001, 45% in 2013, P &amp;lt; 0.001). Simultaneously, 30-day survival rose from 5% in 2001 to 12% in 2013, P &amp;lt; 0.001. Among patients achieving ROSC, a larger proportion underwent acute CAG/PCI (5% in 2001, 27% in 2013, P &amp;lt; 0.001). The proportion of patients undergoing acute CAG/PCI annually in each region was defined as the CAG/PCI index. The following variables were associated with lower mortality in multivariable analyses: direct admission to invasive heart centre (HR 0.91, 95% CI: 0.89–0.93), CAG/PCI index (HR 0.33, 95% CI: 0.25–0.45), population density above 2000 per square kilometre (HR 0.94, 95% CI: 0.89–0.98), bystander CPR (HR 0.97, 95% CI: 0.95–0.99) and witnessed OHCA (HR 0.87, 95% CI: 0.85–0.89), whereas distance to the nearest invasive centre was not associated with survival. Conclusion Admission to an invasive heart centre and regional performance of acute CAG/PCI were associated with improved survival in OHCA patients, whereas distance to the invasive centre was not. These results support a centralized strategy for immediate post-resuscitation care in OHCA patients. </jats:sec